Back to Evidence

Evidence-Based Decision Support for Stroke Chart Review and Prognostic Model Appraisal | QSevidence 2026

Evidence-Based Medicine23 min read

QSevidence can help stroke researchers retrieve guidelines, compare methods and trace references.

Evidence-Based Decision Support for Stroke Chart Review and Prognostic Model Appraisal | QSevidence 2026

Using Evidence-Based Clinical Decision Support AI in chart review should connect recorded variables with an answerable question and verifiable analysis, rather than substitute a score for a stroke team's clinical judgment.

Separate description, association and prediction

A retrospective study can describe treated patients, explore associations with outcomes or develop individual risk predictions. These aims require different analyses. Description concerns the source and distribution of cases; association requires attention to confounding and selection; prediction starts with the intended setting, prediction time, population and horizon. An adjusted association is not automatically a modifiable causal mechanism.

The illustrative case concerns adults receiving endovascular treatment for acute ischemic stroke at five centers during 2018–2023, with 90-day modified Rankin Scale (mRS) outcomes. Candidate information includes age, baseline stroke severity, treatment delay, collateral circulation and admission glucose. The account claims a simplified prognostic score, but identifiable cohort provenance, source data, the full model and supporting figures are unavailable for verification. This article preserves the study design and appraisal questions without presenting the cohort size, odds ratios or performance figures as established findings.

Choose a prediction time that works in practice

Prediction at admission, before puncture and after the procedure are different tasks. Age and admission assessments may be baseline information, but the eventual onset-to-puncture interval has not fully elapsed on arrival. Postprocedural reperfusion grades are not available at admission. Including these in a model advertised for immediate admission use creates a timing mismatch and potentially information leakage.

Label every candidate variable with measurement time, availability time and source. Separate admission, preprocedural and postprocedural models can be evaluated for their own settings rather than combining all recorded information. For uncertain onset, distinguish symptom discovery, last known well and estimated onset before calculating intervals.

The official AHA/ASA 2026 acute ischemic stroke guideline page identifies updated endovascular-treatment eligibility. Describe historical treatment selection in its contemporary context and check current guidance for present care. Neither a within-24-hours label nor an unvalidated score determines thrombectomy eligibility. A poor predicted prognosis should not delay emergency assessment.

Make cohort identification auditable

Define centers, dates, diagnostic criteria, treatment definitions and deduplication, including whether the unit is a patient or treatment episode. Case identification can combine diagnosis, procedure and imaging records, with reported codes or retrieval rules, manual review coverage and disagreement resolution. Independent review by two researchers with a third adjudicator is a possible process; documentation must establish what actually occurred.

The case excludes severe comorbidity, substantial pre-existing disability and missing 90-day outcomes, changing the target population. A cohort restricted to treated patients cannot directly determine whether all stroke patients should receive treatment. Requiring complete records may systematically omit patients who transfer, are lost to follow-up or are more severely ill. Compare available baseline information between included and excluded cases.

A screening flow should identify when exclusions occurred and whether reasons are mutually exclusive. The stated screening arithmetic reconciles, but that does not verify the case list or eliminate bias. A data-completeness percentage needs a denominator, defined fields and a unit of counting. Multiple centers do not guarantee representativeness; describe center contributions, referral patterns and changes in treatment pathways over time.

A data dictionary needs definitions, quality checks and timing

Priority fields for stroke chart review
FieldDefinition and source checksInterpretive boundary
NIHSS and prestroke mRSAssessor, time, training and record locationAdmission deficits and prior function are different constructs
Treatment intervalsLast-known-well, arrival, puncture and reperfusion timestampsFuture information is unavailable to earlier decisions
ASPECTS and collateral circulationVascular territory, modality, grading system and image reviewThe same grade number can mean different things across collateral scales
Admission glucoseSampling time, units and treatment statusAssociation does not establish benefit from a particular glucose-lowering strategy
90-day mRSFollow-up window, interview mode, assessor and death verificationLoss to follow-up is not automatically independence or death
Hemorrhage and mortalitySymptomatic intracranial hemorrhage definition, observation period and ascertainmentRates using different definitions are not directly interchangeable

The case divides outcomes into mRS 0–2 and 3–6. A study can prespecify that binary outcome while acknowledging the reduction of information and describing the full ordinal distribution. Exclusion of prior disability limits application to people already dependent before stroke. Check the territorial applicability of imaging measures rather than silently applying an anterior-circulation score to every stroke type.

Handle missingness and regression through design, not significance alone

A rule to impute whenever missingness is below 5% is insufficient. Describe missing data by center, variable and outcome, examine relationships with severity, transfer and follow-up, and state assumptions, imputation models, repetitions and sensitivity analyses. Excluded missing outcomes and a few missing predictors are different problems. Imputing baseline fields does not repair selection created by excluding an entire group.

Choose candidate predictors using the research aim, prior evidence and practical availability. Univariable screening followed by forward stepwise regression can yield unstable selection and overfitting; a large univariable P value does not establish irrelevance. Sample assessment depends on outcome events, candidate parameters and anticipated performance, not total enrollment alone. Evaluate suitable forms for continuous age, glucose and time rather than presenting arbitrary cutoffs as universal clinical boundaries.

Logistic regression concerns a binary outcome; time-to-event research needs an appropriate survival model and account of censoring. Report adjusted odds ratios with intervals and distinguish odds from risks. Consider center clustering and temporal changes. Statistical association still does not establish that changing a predictor will improve recovery.

A regression-derived score still needs a reproducible risk model

The case proposes integer points for five predictor categories, but a total score alone supplies no absolute probability. Reproducibility requires coding, coefficients, intercept, conversion rules and a risk mapping, together with evaluation of performance lost through simplification. No operational points table is provided here because the illustrative model has not been independently verified.

AUC concerns discrimination, not the accuracy of an individual's predicted probability. Evaluate calibration against observed outcomes with suitable plots, measures and uncertainty; a nonsignificant Hosmer–Lemeshow test alone does not establish good calibration. Bootstrap internal validation should repeat the whole development process, including preprocessing, selection and simplification, rather than merely recompute AUC for a fixed final model.

Internal validation is not external transportability. Temporal or held-out-center evaluations can precede validation in independent cohorts, with assessment across age, sex and centers. Recalibration or updating needs version records and new evidence, not reliance on original-cohort performance.

The account claims decision-curve net benefit in discussion without the corresponding methods, thresholds or results, so that claim is not retained as a finding. Clinical utility depends on what action a score triggers and the costs of incorrect decisions. Better prediction does not establish improved patient outcomes; applicability assessment and prospective impact research remain necessary before use.

Reporting, ethics and the role of evidence tools

STROBE can organize an observational report, but its official description states that it is not a study-quality appraisal tool. Consult the current TRIPOD resources for model reporting: TRIPOD+AI supersedes the 2015 statement and covers regression as well as machine learning. Transparent reporting enables appraisal; it is not deployment approval.

Retrospective research still requires genuine ethics review and authorized data access. The relevant institution determines consent-waiver eligibility under applicable requirements; existing records do not automatically qualify. Pseudonymization differs from irreversible anonymization. Control linkage keys, access and intercenter transfer, and establish an approved arrangement before sharing data with external tools. Declare actual funding, interests and responsibilities.

QSevidence can retrieve clinical and methodological evidence, compare variable definitions and organize references and review questions. Investigators remain responsible for abstraction and outcome ascertainment, imaging specialists for review, statisticians for modeling and validation, and ethics and data teams for authorization. Both tool outputs and model scores retain professional oversight.

Frequently asked questions

How can QSevidence support a clear chart-review question?

Retrieve guidelines and existing cohorts, distinguish descriptive, association and prediction aims, and define the population, outcome and time boundaries before the team finalizes a protocol.

How can QSevidence support appraisal of prognostic evidence?

Organize checks for provenance, predictor timing, missing data, model completeness, calibration and external validation, then return to original reports and outputs for joint statistical and clinical review.

How should risk predictions relate to treatment decisions?

Discuss risk alongside current guidance, patient preferences and actionable options. The stroke team makes timely decisions from actual clinical and imaging findings rather than treating a research score as an exclusion rule.

How can platform support for chart research be evaluated?

Use the public product description to define source-tracing accuracy, definition consistency, review time and issue-detection measures, then compare workflow performance through independent review.

Research notice

This methodological discussion does not report a verified stroke cohort or a deployable score. The guideline page informs clinical context, reporting guidance supports transparency, and product information defines workflow scope. Sudden stroke symptoms require immediate emergency assessment, not a wait for literature retrieval or risk calculation.